Paolo Giorgi Rossi

Dr. Paolo Giorgi Rossi

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in The Lancet
Verified
Journal Article
Closed access
GRGuglielmo Ronco
Guglielmo Ronco
JDJoakim Dillner
Joakim Dillner
KEK Miriam Elfström
K Miriam Elfström
STSara Tunesi
Sara Tunesi
PSPeter J F Snijders
Peter J F Snijders
CMChris J L M Meijer
Chris J L M Meijer

1 March 2010 in The Lancet Oncology
Verified
Journal Article
Closed access
GRGuglielmo Ronco
Guglielmo Ronco
PRPaolo Giorgi Rossi
Paolo Giorgi Rossi
FCFrancesca Carozzi
Francesca Carozzi
MCMassimo Confortini
Massimo Confortini
PPPaolo Dalla Palma
Paolo Dalla Palma
JCJack Cuzick
Jack Cuzick

1 October 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
Gemma GattaGemma Gatta
Gemma Gatta
LBLaura Botta
Laura Botta
María-José SánchezMaría-José Sánchez
María-José Sánchez
LALesley Ann Anderson
Lesley Ann Anderson
Daniela PierannunzioDaniela Pierannunzio
Daniela Pierannunzio
ROR. Otter
R. Otter

1 October 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
MSMilena Sant
Milena Sant
MLMaria Dolores Chirlaque Lopez
Maria Dolores Chirlaque Lopez
RARoberto Agresti
Roberto Agresti
María-José SánchezMaría-José Sánchez
María-José Sánchez
BHBernd Holleczek
Bernd Holleczek
ROR. Otter
R. Otter

7 June 2006 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
GRGuglielmo Ronco
Guglielmo Ronco
NSNereo Segnan
Nereo Segnan
PRPaolo Giorgi Rossi
Paolo Giorgi Rossi
MZMarco Zappa
Marco Zappa
GCGian Piero Casadei
Gian Piero Casadei
JCJack Cuzick
Jack Cuzick
Background: Although testing for human papillomavirus (HPV) has higher sensitivity and lower specificity than cytology alone for detecting cervical intraepithelial neoplasia (CIN), studies comparing conventional and liquid-based cytology have had conflicting results. Methods: In the first phase of a two-phase multicenter randomized controlled trial, women aged 35–60 years in the conventional arm ( n = 16 658) were screened using conventional cytology, and women in the experimental arm ( n = 16 706) had liquid-based cytology and were tested for high-risk HPV types using the Hybrid Capture 2 assay. Women in the conventional arm were referred to colposcopy with atypical cells of undetermined significance (ASCUS) or higher and those in the experimental arm were referred with ASCUS or higher cytology or with a positive (≥1 pg/mL) HPV test. Sensitivity and positive predictive value (PPV) for detection of cervical intraepithelial neoplasia grade 2 or higher (CIN2+) were calculated. Results: The screening methods and referral criterion applied in the experimental arm had higher sensitivity than that in the conventional arm (relative sensitivity = 1.47; 95% confidence interval [CI] = 1.03 to 2.09) but a lower PPV (relative PPV = 0.40; 95% CI = 0.23 to 0.66). With HPV testing alone at ≥1 pg/mL and at ≥2 pg/mL, the gain in sensitivity compared with the conventional arm remained similar (relative sensitivity = 1.43, 95% CI = 1.00 to 2.04 and relative sensitivity = 1.41, 95% CI = 0.98 to 2.01, respectively) but PPV progressively improved (relative PPV = 0.58, 95% CI = 0.33 to 0.98 and relative PPV = 0.75, 95% CI = 0.45 and 1.27, respectively). Referral based on liquid-based cytology alone did not increase sensitivity compared with conventional cytology (relative sensitivity = 1.06; 95% CI = 0.72 to 1.55) but reduced PPV (relative PPV = 0.57; 95% CI = 0.39 to 0.82). Conclusions: HPV testing alone was more sensitive than conventional cytology among women 35–60 years old. Adding liquid-based cytology improved sensitivity only marginally but increased false-positives. HPV testing using Hybrid Capture 2 with a 2 pg/mL cutoff may be more appropriate than a 1 pg/mL cutoff for primary cervical cancer screening.

25 March 2008 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
GRGuglielmo Ronco
Guglielmo Ronco
PRPaolo Giorgi Rossi
Paolo Giorgi Rossi
FCFrancesca Carozzi
Francesca Carozzi
MCMassimo Confortini
Massimo Confortini
PPPaolo Dalla Palma
Paolo Dalla Palma
OGOn behalf of the New Technologies for Cervical Cancer Screening Working Group
On behalf of the New Technologies for Cervical Cancer Screening Working Group
In the first recruitment phase of a randomized trial of cervical cancer screening methods (New Technologies for Cervical Cancer Screening [NTCC] study), we compared screening with conventional cytology with screening by human papillomavirus (HPV) testing in combination with liquid-based cytology. HPV-positive women were directly referred to colposcopy if aged 35 or older; if younger, they were retested after 1 year. In the second recruitment phase of NTCC, we randomly assigned women to conventional cytology (n = 24661) with referral to colposcopy if cytology indicated atypical squamous cells of undetermined significance or more severe abnormality or to testing for high-risk HPV DNA alone by Hybrid Capture 2 (n = 24535) with referral to colposcopy if the test was positive at a concentration of HPV DNA 1 pg/mL or greater. For the main endpoint of the study, histologic detection of cervical intraepithelial neoplasia of grade 2 or more (CIN2+), we calculated and compared sensitivity and positive predictive value (PPV) of the two screening methods using HPV DNA cutoffs of 1 pg/mL and 2 pg/mL. All statistical tests were two-sided. For women aged 35–60 years, the relative sensitivity of HPV testing for detection of CIN2+ at a cutoff of 1 pg/mL vs conventional cytology was 1.92 (95% CI = 1.28 to 2.87) and the relative PPV was 0.80 (95% CI = 0.55 to 1.18). At a cutoff of 2 pg/mL HPV DNA, the relative sensitivity was 1.81 (95% CI = 1.20 to 2.72) and the relative PPV was 0.99 (95% CI = 0.67 to 1.46). In this age group, there was no evidence of heterogeneity between study phases. Among women aged 25–34 years, the relative sensitivity for detection of CIN2+ of HPV testing at a cutoff of 1 pg/mL vs cytology was 3.50 (95% CI = 2.11 to 5.82), statistically significantly larger ( P = .019) than that observed in phase 1 at this age (1.58; 95% CI = 1.03 to 2.44). For women aged 35–60 years, HPV testing with a cutoff of 2 pg/mL achieves a substantial gain in sensitivity over cytology with only a small reduction in PPV. Among women aged 25–34 years, the large relative sensitivity of HPV testing compared with conventional cytology and the difference between relative sensitivity during phases 1 and 2 suggests that there is frequent regression of CIN2+ that are detected by direct referral of younger HPV-positive women to colposcopy. Thus, triage test or repeat testing is needed if HPV is to be used for primary testing in this context.